After the PCAC votes: what FDA reclassification actually looks like in practice

Say the July vote goes the way you’re hoping. BPC-157 gets a favourable recommendation. Here’s the part the forums skip: you still can’t fill a prescription in August. Or September. Maybe not in 2026 at all.

The vote isn’t the access. Between a favourable PCAC recommendation and a vial a US pharmacy can legally hand you sits a formal, public, unhurried process called rulemaking. That process is where your access actually changes — not the meeting. What the PCAC is and what its vote decides is the companion to this piece. This one is about everything that happens after the gavel comes down.

The vote recommends. Then the FDA writes the rule.

The committee’s job is to advise. It meets, hears testimony, deliberates, and votes — and that vote is a recommendation to the agency, not a regulation and not a permission to dispense. The FDA takes it as input and writes the actual rule for the Section 503A bulk drug substances list on its own schedule.

That one fact sets the pace of everything downstream. In rough shape, the road from a favourable July vote to a prescription you can fill runs through four stages:

• The vote. Recorded on the day, published in the meeting summary, tallied by named member. Splits are on the record.
• The proposed rule. The FDA publishes a notice of proposed rulemaking in the Federal Register that adds the substance to the 503A list — or doesn’t — for the indication the committee reviewed. A public comment period opens, usually thirty to ninety days.
• The final rule. After comments close, the agency reviews them and publishes the final rule. This is the document that legally changes the list. Until it publishes, nothing has moved for pharmacies.
• Compounding begins. Once the final rule is in effect, US-licensed compounding pharmacies — both 503A traditional pharmacies and 503B outsourcing facilities — can make the substance for the indication on the list, on prescriptions written for named patients.

Each step takes weeks at a floor and months in practice. There’s no version where a July vote is a fillable script in August.

The indication is the whole game

The most consequential thing about the rule is the indication stapled to it. PCAC votes on a substance for one specific use, and the rulemaking ties the compounding allowance to that use.

For BPC-157, the docketed indication is ulcerative colitis. If the committee recommends inclusion and the FDA writes it in, what a pharmacy gains is the legal allowance to compound BPC-157 for ulcerative colitis. A doctor prescribing it for a torn shoulder is then writing off-label use of a compounded drug — not illegal, but a decision that lands squarely on the supervising physician, with the informed-consent conversation that comes with it.

That shape repeats down the docket. The compounding floor sits at the indication on the rule. Everything past it is clinical judgement and your consent — a more careful conversation than a checkout page, but a real one, in a way a research-chemical vial never was.

An unfavourable vote — and the four that already lost

An unfavourable vote doesn’t ban a compound by itself. It signals the recommended position is exclusion, and the FDA’s rulemaking will almost certainly follow. The compound stays outside the compounding pathway, and the off-label supply chain remains the only one.

This is already the present tense for four peptides the forums still treat as in play. CJC-1295, ipamorelin, AOD-9604, and Thymosin alpha-1 went to PCAC in 2024 — ipamorelin at the October 29 meeting, the other three on December 4 — and the committee voted against all four. None has a US compounding pathway today. None is getting another PCAC review in 2026 or 2027. Treating them as still-pending doesn’t match the record; the door was walked through, and it closed.

What actually changes for you when the final rule lands

Three things, concretely.

Your doctor can write a prescription for the named indication, knowing the compound is on the 503A list and a US pharmacy can fill it. The question moves from where do I source this to should I take this, for this.

A licensed pharmacy can source the bulk substance through legitimate channels, with documented identity, purity, and potency testing — the same quality framework every other compounded drug runs under.

And you receive a labelled vial at a known concentration, made by a pharmacy under federal and state inspection. It hasn’t been through full FDA drug approval. But there’s a real floor under it, which is more than the current market offers.

What doesn’t change overnight is breadth. The 503A list authorises the indication on the list, not the supplement-market pitch around it. Off-label prescribing stays a physician decision under the usual standards. The marketing use and the clinical use are still two different conversations after the rule publishes.

How long, honestly

Federal rulemaking on the 503A list has historically run anywhere from several months to more than a year between a PCAC vote and a final rule, and there’s no statutory clock forcing the July or February timelines to move faster. A best case from a favourable July vote to a final rule in effect is probably late 2026 to mid-2027. The typical case is longer. A contested one — heavy comment volume, a revised proposed rule — can stretch into 2028.

So the honest read: whatever the committee recommends in July, the access change is a 2027 conversation at the earliest for most of the seven July compounds, and 2028 for the five in the February wave. The vote is the direction. The rule is the event.

Where this leaves you now

Until a final rule publishes, the only supply chain for all twelve peptides across both waves runs through research-chemical vendors — not for human consumption labels, no testing of identity or purity, no prescription, no physician, no recourse if a vial turns up under-dosed or carrying the wrong compound entirely. The PCAC process is the legal route out of that. It just isn’t a fast one.

Wolverine Health is being built to move on the rule, not the vote — physician-supervised prescriptions, US-licensed compounding, third-party-tested batches, the day each final rule turns real. Leave your email and we’ll tell you when the peptide you’re tracking is something a pharmacy can put your name on.